The Centers for Medicare & Medicaid Services yesterday a new payment and service delivery model as part of a multi-pronged strategy to combat the nation’s opioid crisis. The goals of the  are to improve the quality of care for children under 21 years of age covered by Medicaid and the Children’s Health Insurance Program, reduce avoidable inpatient stays and out-of-home placement, and create sustainable alternative payment models, according to CMS.
 
The InCK Model will support states and local providers in their efforts to conduct early identification and treatment of children with health-related needs across settings. Participants will be required to integrate care coordination and case management across physical and behavioral health and other local service providers to deliver child-and family-centered care. Through the APM that is developed through this model, states and local providers will share accountability for cost and outcomes, CMS said.
 
CMS’s Center for Medicare and Medicaid Innovation Center anticipates releasing a notice of funding opportunity this fall with additional details on how state Medicaid agencies and local health and community-based organizations can apply to participate in the model. CMS intends to award funding for up to eight states at a maximum of $16 million each as early as next spring to implement the seven-year model.
 

Related News Articles

Perspective
Patient-centered care strategies and models that emphasize the importance of understanding and responding to patient preferences, needs and values. More care…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
The Center for Medicare and Medicaid Innovation yesterday released its 2024 Report to Congress that includes updates on 37 models and initiatives (including…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…